Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NIDDK’s Diabetes Control & Complication Trial

Executive Summary

Study group on the trial is scheduled to meet in early June; the trial could be ended early due to favorable results, which might be reported as soon as this year's American Diabetes Association meeting June 12-15. Amylin Pharmaceuticals Chairman Howard Green predicts at Alex. Brown conference that the DCCT trial will draw increased attention to glucose control as a means of avoiding the onset of retinopathy but will highlight the risk of hypoglycemia. Green maintains that amylin replacement therapy is the only glucose control treatment in clinical trials that directly addresses this risk.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS022623

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel